Skip to main content
Signal8

Hemogenyx Pharmaceuticals Plc (HOPHF)

Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments. Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies. Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.

Sector: Biotechnology

Industry: Biotechnology

Hemogenyx Pharmaceuticals Plc logo

Hemogenyx Pharmaceuticals Plc

OTC:HOPHFHealthcare
Mkt Cap-
EV-
Float3.88M
O/S6.9M
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution